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Abstract:  
 
Adults with atrial fibrillation are at an increased risk for stroke. New oral antithrombotic agents 
are now available to help prevent stroke and other thromboembolic events. This article provides 
an update on factors to consider when determining various treatment options for these high-risk 
patients in hopes of improving outcomes. 
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Article: 
 
Atrial fibrillation (AF) is a relatively common cardiac dysrhythmia in adults (see Identifying AF). 
In fact, a 40-year-old adult has about a one in four chance of developing AF in his or her 
remaining lifetime.1 The average male and female develop AF at age 66.8 years and 74.6 years, 
respectively.1  
   
Having AF is associated with a two- to threefold increase in mortality.1 Furthermore, patients 
with AF are more likely to develop heart failure, dementia, and are four to five times more likely 
to have an ischemic stroke as compared to those patients without AF.1 However, the risk of 
stroke in patients with AF is quite variable, ranging from 1% to 20% annually, depending on 
comorbidities, age, and whether there is a prior history of stroke.2 
 
Figure. Identifying AF 
AF is an atrial dysrhythmia characterized by chaotic, asynchronous electrical activity. It results 
from firing of multiple impulses from numerous ectopic pacemaker sites in the atria. P waves 
are absent and the ventricular response is irregularly irregular. 
 
FIGURE IS OMITTED FROM THIS FORMATTED DOCUMENT 
Source: ECG Interpretation: An Incredibly Easy Pocket Guide. Philadelphia, PA: Lippincott 
Williams & Wilkins; 2006:70. 
 
Types of AF and treatment goals 
 
Traditionally AF has been classified as being acute (lasting less than 48 hours) or chronic. 
However, a better classification scheme is to distinguish whether the patient with AF has first-
detected (first diagnosed) episode or recurrent AF (2 or more episodes). Recurrent episodes can 
then be further classified into paroxysmal AF (recurrent AF lasting less than 7 days that 
spontaneously returns to normal sinus rhythm without treatment); persistent AF (recurrent AF 
lasting more than 7 days requiring treatment to convert to normal sinus rhythm); or the AF may 
progress to become permanent.3  
 
Since patients may have more than one type of chronic AF over their lifetime, they are 
categorized by with the type that presents most frequently.3 
 
Paroxysmal, persistent, and permanent AF are associated with an increased risk of stroke to a 
similar degree1; therefore, one of the most important treatment goals for chronic AF is to prevent 
stroke and other thromboembolic events. Other major treatment goals (beyond the scope of this 
article) are to control the ventricular heart rate during episodes of AF and to restore normal sinus 
rhythm for some patients in persistent AF. 
 
Assessing stroke risk in patients with chronic AF 
 
It is important for nurse practitioners (NPs) to risk stratifying patients with AF to determine who, 
given the risks and benefits, would be the best match for these agents.2 One commonly used risk 
stratification tool recommended by the American Heart Association is the CHADS2 scoring 
schema2,4 (see CHADS2 scoring schema for calculating stroke risk in patients with AF). The 
CHADS2 score takes into account stroke risk factors for patients with AF and assigns points for 
each risk factor. Each letter in the acronym stands for the condition/comorbidity that has been 
identified as a stroke risk factor. A prior history of stroke or transient ischemic attack earns 
patients two points (as indicated by the “S2” in the acronym) as the highest relative risk factor for 
having a stroke. 
 
Table. CHADS2 scoring schema for calculating stroke risk in patients with AF2, 4, 6 
Condition or comorbidity Points 
Congestive heart failure* 1 point 
Hypertension (or treated hypertension) 1 point 
Age 75 years or older 1 point 
Diabetes mellitus 1 point 
Prior stroke or transient ischemic attack 2 points 
*The term “congestive HF” has been replaced in many sources with “cardiac HF” 
 
Higher CHADS2 scores equate with a higher likelihood of stroke risk for the patient. For 
example, a patient with a score of 0 to 1 has a relatively low stroke risk (less than 3% per year).4 
Patients with CHADS2 scores of 2 or 3 have a higher relative risk of stroke (4% to 6% per year).4 
A score of 4 to 5 yields approximately an 8.5% to 12.5% each year,4 whereas a patient with the 
maximum score (6) has the highest risk of stroke (~18% per year).4 Overall, the CHADS2 
scoring schema offers clinicians an objective, user-friendly measure for determining which 
patients are at the highest risk for stroke. 
 
A second, more refined risk stratification instrument, the CHA2DS2 VASc scoring schema, 
includes additional risk factors for stroke into the total score (ages 65 to 74 years, female gender, 
and vascular disease).5 However, these additional risk factors are less validated and are not 
currently recommended in the U.S. guidelines. 
 
Table. Stroke prevention treatment recommendations for AF based on CHADS2 score6 
Score Stroke risk Treatment recommendation 
0 Low risk No therapy. If therapy is chosen, aspirin. 
1 Moderate risk Oral antithrombotic therapy is recommended over aspirin or the 
combination of aspirin/clopiogrel. 
≥ 2 High risk Oral antithrombotic therapy. 
 
Stroke prevention for patients with nonvalvular AF 
 
The American College of Chest Physicians offers evidence-based recommendations for 
antithrombotic prophylaxis for stroke in patients with nonvalvular AF6 (see Stroke prevention 
treatment recommendations for AF based on CHADS2 score). According to these 
recommendations, patients with a CHADS2 score of “0,” who are at a very low stroke risk, 
should not be treated with antithrombotic therapy. For patients who choose therapy, it is 
suggested that aspirin alone be used rather than antithrombotic therapy or a combination of 
aspirin and clopidogrel. For patients at an intermediate risk of stroke (CHADS2 score of 1), oral 
antithrombotic therapy is recommended over aspirin or combination therapy of aspirin and 
clopidogrel.2 However, there remains variability in the recommendation for treatment for 
patients with a CHADS2 score of “1.” This group of patients has a relatively moderate risk for 
stroke and, therefore, requires a more individualized approach to weighing risk versus benefit. 
Finally, for those at high risk of stroke (CHADS2 score of 2 or greater), antithrombotic therapy is 
recommended unless contraindicated.6 
 
Antithrombotic agents currently available 
 
Vitamin K antagonists.  
 
Warfarin, a vitamin K antagonist, has traditionally been the treatment of choice for stroke 
prevention in patients with AF. The medication is relatively inexpensive and, until recently, was 
the most efficacious agent on the market to prevent stroke in patients with AF. However, there 
are two major drawbacks that arise with warfarin use. The first is that warfarin is frequently 
underutilized by providers and patients, in part, due to the risk of bleeding, especially in older 
adults. The second challenge relates to the difficulty in keeping the medication in the desired 
therapeutic range. It is estimated that only about 58% of those patients who are taking warfarin 
are within the desired therapeutic range.7 Reasons for this difficulty include the pharmacologic 
properties of the drug (a narrow therapeutic window, unpredictable anticoagulant effects, genetic 
variability in metabolism, and multiple drug-drug and drug-food interactions) and the 
inconvenience of monitoring of drug levels.7 Subtherapeutic drug levels place the patient at an 
increased risk for stroke, whereas drug levels above the therapeutic range place the patient at risk 
for bleeding. 
 
Table. Antithrombotic treatment options for stroke prevention in nonvalvular AF8-11 
Antithrombotic 
agent/ Mechanism 
of action 
Dosing information Key nursing 
implications 
Warfarin  
Vitamin K 
antagonist 
• Peak effect 72 to 96 hours. 
• Mean half-life 40 hours. 
• Dose varies (dose is individualized). Typically, 
the starting oral dose is between 2 to 5 mg once 
daily, in the evening. 
• No dosage adjustment with kidney impairment. 
• Requires ongoing 
lab monitoring. INR 
goal: 2.0 to 3.0 for 
nonvalvular AF. 
• Antidote: Vitamin 
K. 
Dabigatran direct 
thrombin inhibitor 
(also known as a 
factor IIa inhibitor 
• Peak effect 1 to 2 hours. 
• Half-life 12 to 17 hours. 
• Patients with CrCl > 30 mL/minute the dose is 
150 mg orally twice daily 
• Patients with CrCl 15 to 30 mL/minute the 
dose is 75 mg orally twice daily 
• No dosing information is available if CrCl < 15 
mL/min or if patients are on dialysis. 
• Requires no lab 
 monitoring. 
• No specific 
antidote. 
• Patients must be 
able to swallow 
capsules. 
Rivaroxaban  
Direct factor Xa 
inhibitor 
• Peak effect 2 to 4 hours. 
• Half-life 5 to 9 hours; 11 to 13 hours for older 
adults or those with CKD. 
• Patients with CrCl > 50 mL/minute the oral 
dose is 20 mg daily with the evening meal 
• Patients with CrCl 15 to 50 mL/minute the oral 
dose is 15 mg daily with the evening meal 
• Do not use if CrCl < 15 mL/min. 
• Stop the drug if the patient develops acute renal 
failure. 
• Requires no lab 
monitoring. 
• No specific 
antidote. 
• Administer with 
food to increase 
bioavailability. 
Apixaban  
Direct factor Xa 
inhibitor 
• Peak effect 3 to 4 hours. 
• Half-life 12 hours. 
• Recommended oral dose is 5 mg twice daily 
for most patients. 
• Recommended oral dose is 2.5 mg twice daily 
for patients with at least two of the following: 
age ≥ 80 years, body weight of ≤ 60 kg, or serum 
creatinine of ≥ 1.5 mg/dL. 
• No dosing information if CrCl < 15 mL/min or 
if on dialysis. 
• Requires no lab 
monitoring. 
• No specific 
antidote. 
CrCl = Creatinine Clearance; INR = International Normalized Ratio 
 
 
 
 
New antithrombotic agents.  
 
Three alternative antithrombotic agents to warfarin have recently been approved by the USFDA; 
dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) (see Antithrombotic 
treatment options for stroke prevention in nonvalvular AF).8–11 The FDA approved the new 
agents for patients with nonvalvular AF (AF not caused by valvular heart disease or those with 
mechanical heart valves). All others who need chronic anticoagulation for stroke prevention 
should be treated with warfarin. 
 
All three alternative agents have been studied in comparison to warfarin and performed the same 
or better than warfarin in relation to efficacy and safety. In an indirect comparison of the new 
medications, as compared to warfarin, all offered an advantage of fewer strokes and systemic 
emboli and provided an additional 10% reduction in mortality.7 Furthermore, as compared to 
warfarin, all three agents are associated with lower bleeding rates (including fewer hemorrhagic 
strokes, intracranial hemorrhages, and major bleeds).7 
 
Dabigatran, the first FDA-approved alternative to warfarin, is a direct thrombin inhibitor (factor 
IIa inhibitor). This medication is a prodrug that peaks within a few hours and is eliminated 
primarily by the kidneys.8 Dabigatran has a half-life of approximately 12 to 17 hours in patients 
with a normal creatinine clearance (CrCl).8 The prescribed daily oral dose is based on the 
patient's CrCl.8 Do not prescribe for those with severe kidney impairment (CrCl < 15 mL/min).8 
 
Rivaroxaban, the second FDA-approved alternative to warfarin, is a direct factor Xa inhibitor. 
Like dabigatran, rivaroxaban peaks fairly quickly. This medication has a half-life of 
approximately 5 to 9 hours in healthy adults (ages 20 to 45 years) and is 50% higher in older 
adults or in those with chronic kidney disease (CKD) (11 to 13 hours).9 However, unlike 
dabigatran, rivaroxaban is only partially eliminated by the kidneys (~33%).9 The prescribed, 
once-daily oral dose is based on the patient's CrCl.9 
 
Apixaban, the third FDA-approved alternative to warfarin, is also a direct factor Xa inhibitor. 
The medication, similar to the other two antithrombotic agents, peaks within a few hours and has 
a half-life of approximately 12 hours.10 However, apixaban is primarily eliminated through the 
intestines and only partially eliminated by the kidneys (27%)10; it is prescribed twice daily at 5 
mg. Per the packet insert, if the patient has at least two of the following: age > 80 years, body 
weight of < 60 kg, or a serum creatinine of > 1.5 mg/dL, the recommended dose is 2.5 mg twice 
daily.10 
 
Contraindications to chronic antithrombotic therapy 
 
Contraindications to warfarin include active bleeding or conditions that place the individual at 
high risk for major bleeding (blood dyscrasias, recent or anticipated surgery of the central 
nervous system, spinal puncture, other diagnostic/therapeutic procedures that have the potential 
for uncontrollable bleeding, or major regional/lumbar block anesthesia). Additional 
contraindications to warfarin include a known hypersensitivity to warfarin, malignant 
hypertension, pregnancy (except in the case of women who have mechanical heart valves), and 
use in unsupervised patients who have the high potential for nonadherence.11 
 
Contraindications to the newer antithrombotic agents include the following: active bleeding or 
the potential for major bleeding, known hypersensitivity to any of the medications that are being 
considered, those with prosthetic valves or those with hemodynamically significant valvular 
heart disease, women who are pregnant or breastfeeding, those with severe kidney failure (CrCl 
< 15 mL/min) or advanced liver disease (impaired baseline clotting function), and unsupervised 
patients who have the high potential for nonadherence.8–10  
 
Safety concerns of antithrombotic agents 
 
The primary safety concern for any antithrombotic agent is major bleeding. Major bleeding may 
be classified as fatal bleeds, hemorrhagic stroke, intraocular bleeds, and gastrointestinal bleeds. 
In general, however, all of these bleeding events combined occur infrequently (~2% to 4% per 
year) for both warfarin and the newer agents.7 Based on data from the clinical trials, hemorrhagic 
strokes occur approximately 0.10% to 0.47% per year, which was less likely in patients who 
have received the newer agents in the clinical trials (0.10% to 0.26%/year).7 
 
Patients who are at highest risk for bleeding should be identified in advance of starting 
antithrombotic therapy. For example, certain risk factors for bleeding are also absolute or relative 
contraindications to starting therapy at all. These include the following: a history of bleeding 
(greatest risk factor for bleeding) or a predisposition for bleeding, abnormal liver or kidney 
disease, uncontrolled hypertension, concomitant drug or alcohol use, reduced platelet 
count/function, excessive fall risk, and malignancy.12,13 Other risk factors for bleeding, however, 
are also risk factors for having a stroke (prior history of stroke, age of over 65 years, and a 
history of hypertension).12,13 For example, research has shown that the higher a patients' 
CHADS2 score is and the older a patient is, the higher the likelihood there is of bleeding.14 This 
situation creates a challenge for the clinician as to whether to start antithrombotic therapy. 
However, it is important for the clinician to keep in mind, when considering risk-benefit ratios, 
the likelihood of stroke is greater than the likelihood of bleeding in many patients with AF. Thus, 
the clinician should openly discuss the risks/benefits of antithrombotic therapy with each 
individual patient to determine the best treatment plan for stroke prevention.5,7 
 
Management of bleeding 
 
Management of bleeding needs to be taken into consideration in advance of starting any chronic 
antithrombotic therapy. Warfarin has a specific antidote (vitamin K).11 However, at this time, 
none of the newer agents have specific antidotes. 
 
Dabigatran is partially dialyzable, but the data are limited.8 However, the other two new agents 
are not expected to be dialyzable. The use of activated charcoal to reduce absorption of 
rivaroxaban and apixaban may be considered for cases of overdosage.9,10 Furthermore, 
“universal antidotes” for factor Xa inhibitors (rivaroxaban and abixaban) are currently in phase 2 
drug development studies.16  
 
A temporary discontinuation of therapy for the new agents may suffice for management of minor 
bleeds due to the relatively short half-life (ranging from 2 to 4 hours). If discontinued, 
approximately half of the medication will be out of the body within a few hours. 
 
Beyond the use of an antidote (for warfarin), treatment for major bleeding with warfarin 
includes: stopping the agent, applying direct pressure to the bleeding site (if the site is 
compressible), and administering I.V. fluids and blood products as needed (fresh frozen plasma 2 
to 4 units, red blood cells, prothrombin complex concentrate, and/or activated Factor VII).11 
Management of major bleeding for the newer agents, however, is less well established. The use 
of procoagulant reversal agents (prothrombin complex concentrate, activated prothrombin 
complex, or recombinant Factor VIIa) may be helpful, but data are limited, as these have not 
been evaluated in clinical studies.15 
 
Patient education 
 
In general, as with any medication that has the potential to increase the risk of bleeding, all 
patients should be made aware of signs and symptoms of bleeding (unusual bleeding from nose 
or gums, heavier than normal menstrual bleeding, red or brown urine, red or black colored stools, 
hemoptysis, vomiting blood or coffee ground emesis, or unusual bruising or discoloration on the 
skin).8–11 If the patient experiences any of these signs or symptoms, especially if severe, they 
should notify their healthcare provider immediately or seek medical attention right away. 
 
Specific patient education for newer agents.  
 
Because of the relatively short half-life of the new antithrombotic agents, it is very important for 
patients to not miss a dose, therefore, leaving them unprotected for stroke prevention. It is also 
important to instruct patients not to stop their medications abruptly, due to the increased risk of 
stroke (as a result of subtherapeutic drug levels). If they anticipate stopping the medication, they 
should consult with their healthcare provider first. 
 
Patients should be advised not to double up on doses in the event of a missed dose. In the case of 
dabigatran, if the patient realizes that they missed a dose soon after the “usual” time they take the 
medication, they may take the missed dose as long as they can space the next dose out by at least 
6 hours.8 The packet insert for apixaban, the other twice-daily medication, recommends taking 
the missed dose as soon as possible on the same day.10 As with dabigatran, apixaban should not 
be doubled to make up for the missed dose.8,10 
 
It is important to remind patients taking dabigatran to not to open, cut, or crush the capsules. If 
the pellets are taken without the capsule shield, the oral bioavailability is increased by 75%, 
which would place the patient at an increased risk of bleeding.8 Therefore, patients must be able 
to swallow the capsules if prescribed dabigatran. In addition, due to the possibility of 
degradation, the capsules should not be taken out of the pill container or blister pack until they 
are ready to swallow the capsule.8 This means medication boxes for ease of administration 
should not be prefilled by others due to the possible degradation of the capsules. Patients should 
also be advised to use all the capsules within 4 months of opening the bottle.8 
 
Rivaroxaban may be crushed and taken with a small amount of applesauce followed by food for 
patients who are unable to swallow the tablet whole.9 For those with a nasogastric tube or a 
gastric feeding tube, after confirming tube placement, the tablet may be crushed and mixed with 
water and administered via the tube.9 
 
Drug-food and drug-drug interactions 
 
There are many drug-drug and drug-food interactions associated with warfarin. Fewer of these 
interactions exist with the newer antithrombotic agents. The only known food interaction with a 
newer agent involves rivaroxaban (15 or 20 mg doses). This agent should be given with food (the 
evening meal) to maximize the bioavailability of the drug.9 The other two newer agents may be 
taken with or without food.8,10 
 
Some important drug-drug interactions with the newer agents exist, specifically with CYP3A4 
and P-glycoprotein (P-gp) transporter inhibitors and inducers. The packet inserts for the newer 
agents provide specific drug-drug interactions for each of the medications.8–10 For example, for 
rivaroxaban and apixaban (the factor Xa inhibitors), inducers of CYP3A4 and P-gp are known to 
decrease the exposure to the medication, thus, increasing the risk of stroke; therefore, 
concomitant use should be avoided.9,10 These agents, as listed on the packet inserts, include 
rifampin, carbamazepine, phenytoin, and St. John's wort. The packet insert for dabigatran, the 
other new antithrombotic agent, specifies that coadministration with rifampin should also be 
avoided.8 
 
Likewise, strong inhibitors of CYP3A4 and P-gp may increase the risk of bleeding when given 
concurrently with the newer agents. Examples of these agents include ketoconazole, 
itraconazole, ritonavir, and clarithromycin. If concurrently administered with apixaban, a lower 
dose should be prescribed (2.5 mg twice daily).10 Likewise, the dose of dabigatran should be 
decreased (75 mg twice daily) if given to patients with moderate renal impairment (CrCl of 30 to 
50 mL/min) and if given with dronedarone or systemic ketoconazole.8 Concurrent administration 
of any of these agents with rivaroxaban, however, should be avoided all together.9 
 
Finally, as with warfarin, any of the new antithrombotic agents taken concurrently with other 
agents that alter coagulation (aspirin, antiplatelet agents, chronic nonsteroidal anti-inflammatory 
drug use, heparin, and fibrinolytics) can increase the risk of bleeding.8–11 
 
Discontinuation of therapy for surgery or other procedures 
 
In general, the newer antithrombotic agents should be stopped within 24 to 48 hours of elective 
surgery. All three agents should be discontinued at least 48 hours prior to elective surgery or 
invasive procedures that have a moderate-to-high risk of clinically significant bleeding.8–10 
Longer drug-free intervals (3 to 5 days) should be considered for patients who have an altered 
CrCl (CrCl less than 50 mL/min).8–10 However, the surgeon should be consulted to discuss 
specific patient situations. 
 
For elective surgery or invasive procedures that carry a low risk for bleeding, the medications 
should be stopped 24 hours prior to surgery.8–10 After surgery, the medications should be 
resumed when hemostasis is obtained to avoid an extensive drug-free interval, which places the 
patient at risk for stroke. Most dental procedures may be performed safely on full-dose 
medications. However, advise patients to give the dentist the list of their current medications 
prior to the procedure. 
 
Implications for advance practice registered nurses 
 
NPs and other advance practice registered nurses should consider the risks and benefits when 
deciding which therapy to prescribe for stroke prophylaxis in patients with nonvalvular AF. The 
newer antithrombotic agents offer several advantages over warfarin and are more efficacious in 
preventing stroke and systemic emboli as compared to warfarin in addition to a reduction in 
mortality.7,17 The newer agents are associated with a lower likelihood of having a hemorrhagic 
stroke (by 40% to 70%), intracranial hemorrhage (~50%), and less major bleeding as compared 
to warfarin.7,17 The newer agents have a more rapid onset of action, a shorter half-life, and are 
more convenient to prescribe (no dose adjustments or need for international normalized ratio 
[INR] monitoring).7,17,18 
 
There are, however, disadvantages to having patients take the newer agents as compared to 
warfarin. Newer medications are typically associated with a substantial increase in cost as 
compared to medications off patent. In addition, the newer medications do not have a specific 
antidote (whereas warfarin does). Another downside to the newer agents is that they have a much 
shorter half-life as compared to warfarin, so if a patient inadvertently misses a dose, they are 
much more likely to have a stroke as compared to missing a dose of warfarin.8–10,17,18 In addition, 
some patients who have been on warfarin for an extended period of time do not want to “let go” 
of the lab monitoring. Finally, as with any new class of medications that have obtained FDA 
approval, some adverse reactions may not be reported until the medications have been on the 
market for a longer period of time. 
 
When to use which agents.  
 
In general, the most important take-home message for preventing stroke in patients with 
nonvalvular AF is to treat them with any antithrombotic therapy if they have a CHADS2 score of 
1 or more, unless contraindicated. Beyond this general rule, there are a few other tips for 
deciding which agent to place patients on. 
 
When treating patients who are not managing well on warfarin, the consensus is to switch them 
to an alternative agent, as per the prescribing information of the newer agent. This can be done 
once the INR is less than 2.0 for dabigatran and apixaban, and less than 3.0 for rivaroxaban.8–10 
 
When treating patients who are on warfarin and doing well, there are two schools of thought. 
Some experts advise to leave them alone if they are in the therapeutic range most of the time, and 
they are not experiencing any adverse reactions.7 Other experts say to convert all of those (who 
can afford it) to the newer agents due to the increased efficacy and safety profile.7 
 
When treating a third group of patients, those naive to any type of antithrombotic therapy, there 
are also two schools of thought. Some experts say put any patient who can afford it on the newer 
agents; others say it does not matter which agent is used as long as they are on some type of 
stroke prophylaxis7,17; therefore, it is important to discuss the pros and cons of each type of 
therapy with the patient and their family. 
 
When deciding which of the newer agents to choose, indirect comparisons provide insight into 
subtle, but unique advantages for each of the three medications.7,17,18 Dabigatran has the best 
efficacy (for stroke prevention) as compared to the other two agents.7,17 Apixaban has the best 
safety profile (less bleeding).7,17 Rivaroxaban provides more convenient dosing: once a day as 
opposed to twice daily with the other two agents. Finally, for patients with CKD, rivaroxaban 
and apixaban have less renal excretion as compared to dabigatran. 
 
Optimize patient outcomes 
 
NPs should be knowledgeable about how to risk stratify patients with AF to determine who 
needs stroke prophylaxis. For those patients who need therapy, there are new treatment options 
that are available. NPs need to weigh the pros and cons of using new therapy versus conventional 
treatment with warfarin in order to optimize patient outcomes. 
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